Advertisement
Steve Worland, Ph.D., President and Chief Executive Officer of Anadys,will present an overview of Anadys and its three clinical programs: ANA598 andANA773 in hepatitis C and ANA773 in cancer.
Advertisement
The presentation will be simultaneously webcast and can be accessed on theInvestor Relations page of the Company's website athttp://www.anadyspharma.com. Listeners are encouraged to visit the websiteapproximately five minutes prior to the corporate presentation to download orinstall any necessary software. A replay of the presentation will beavailable approximately one hour after the live webcast concludes and will beavailable through November 25, 2008.
About Anadys
Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical companydedicated to improving patient care by developing novel medicines in the areasof hepatitis C and oncology. For the treatment of chronic hepatitis C, theCompany is developing two potentially complementary agents, ANA598, anon-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug.The Company is also developing ANA773 for the treatment of cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical innature constitute "forward-looking statements." Such statements include, butare not limited to, references to Anadys' strategy, development programs, andability to develop novel medicines in the areas of hepatitis C and oncology.Such forward-looking statements involve known and unknown risks, uncertaintiesand other factors, which may cause Anadys' actual results to be materiallydifferent from historical results or from any results expressed or implied bysuch forward-looking statements. For example, the results of preclinical andearly clinical studies may not be predictive of future results, and Anadyscannot provide any assurances that ANA598 and ANA773 will not have unforeseensafety issues, will have favorable results in future clinical trials or willreceive regulatory approval. Risk factors that may cause actual results todiffer are discussed in Anadys' SEC filings, including Anadys' Form 10-K forthe year ended December 31, 2007 and Anadys' Form 10-Q for the quarter endedSeptember 30, 2008. All forward-looking statements are qualified in theirentirety by this cautionary statement. Anadys is providing this informationas of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information,future events or otherwise.
SOURCE Anadys Pharmaceuticals, Inc.
